Navigation Links
Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
Date:12/15/2008

MONTVALE, N.J., Dec. 15 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US: SYI) has dosed the first patient in a 30-patient Phase 2 clinical trial of its proprietary topical GPx-mimetic, SYI-2074, in patients with psoriasis. The trial is planned to be a 28-day multi-center, randomized, double-blind, placebo controlled study to assess the efficacy of topical SYI-2074, applied twice daily, for the treatment of chronic, mild-to-moderate plaque psoriasis in adults. The trial is being conducted in three centers in Israel.

"We are very excited to begin phase 2 clinical trials on SYI-2074 for psoriasis," said Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista Therapeutics. "We believe that there is immense potential to expand the scope of treatment modalities for psoriasis following this trial and look forward to reporting results in the first quarter of 2009."

About SYI-2074

Synvista's GPx mimetic program is based on the rational design of oral and topical drugs that mimic the activity of glutathione peroxidase (GPx), the only enzyme in the human body that reduces oxidized lipids.

GPx is a well validated target for drug development. Animal models have shown that elevated activity of GPx protects animals from experiencing heart attacks and atherosclerosis and reduced levels of GPx put them at risk for those diseases or complications. In humans, research suggests the risk of cardiovascular disease varies inversely with levels of GPx activity (i.e., higher levels of oxidized lipids promote the creation of oxygen free radicals and reactive oxygen species (ROS), such as H2O2, which can promote inflammation).

As noted above, a topical form of our GPx mimetic SYI-2074 is being developed for treatment of mild to moderate plaque psoriasis, an inflammatory disease highly correlated with a molecular signaling
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
2. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
3. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
4. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
5. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
6. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
7. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
8. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
11. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Company plc ("Perrigo") (NYSE: PRGO ; TASE) today ... OTC brands from GSK in an all cash transaction ... demonstration of Perrigo,s unique ability to maximize brand value ... countries.  Perrigo Chairman, President and CEO ... to complete this transaction, which clearly demonstrates our ability ...
(Date:8/28/2015)... HERTFORDSHIRE, England and PITTSBURGH ... (NASDAQ: MYL ) today announced that its ... Company plc (NYSE: PRGO ; TASE) and ... Perrigo,s shareholders at an extraordinary general meeting of ... of two-thirds of the votes cast at the extraordinary general ...
(Date:8/28/2015)... India , August 28, 2015 ... Oils), Livestock (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by Region ... , Asia-Pacific , and Rest of the ... MarketsandMarkets, The global market for Eubiotics was valued at USD ... 7.05 Billion by 2020, at a CAGR of 7.4% from ...
Breaking Medicine Technology:Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
(Date:8/29/2015)... NY (PRWEB) , ... August 29, 2015 , ... ... results and include treating the localized area with stretching, soft tissue manipulation. Platelet ... neutral pelvic position have shown through research to improve treatment outcomes. This ...
(Date:8/28/2015)... Vegas, Nevada (PRWEB) , ... August 28, 2015 , ... ... announcing its decision to make the purchase of CPAP equipment more affordable by offering ... offer includes all types of CPAP products and orders of any size. My Cpap ...
(Date:8/28/2015)... ... 28, 2015 , ... For Dallas, the time is nearing for the annual ... Tenet Health. , The American Heart Association hosts their well-known Heart Walk to raise ... together, a difference can be made. Walkers can participate in the cause and someone ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... those who might personally be struggling with chemical dependency, may be able to ... Drug Rehabilitation, a results-driven holistic treatment center for addiction located in Western Michigan. ...
(Date:8/28/2015)... Neb. (PRWEB) , ... August 28, 2015 , ... Medical ... the 2015 Best Places to Work in Healthcare by Modern Healthcare and ... , Now in its eighth year, the Best Places to Work in ...
Breaking Medicine News(10 mins):Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:My Cpap Store Now Offering Delivery Special 0 Cost to You 2Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3
... television campaign is being launched in Australia to encourage the ... to avoid getting chubby or obese. One in three ... spend six million Australian dollars (US $4.5 million) in its ... receive that important message about the value of exercise, the ...
... are coming to India for the sake of low ... reducing the waistline, rhinoplasty, and breast improvements are very ... in the UK every year. ,Recent ... Surgeons revealed that breast enlargement topped the list of ...
... has said that there is a severe shortage of specialist ... jeopardy. // The report also called for 1,000 consultants to ... ,The report said that the problem was that O&G ... careers would progress when they opted for this specialty. The ...
... of Lords committee report has revealed that about 90% ... have not actually been tested on children. Drugs like ... prescribed to children in spite of them not being ... being given to children have not undergone proper tests ...
... path breaking news that suggests possible links between ... D levels in the mother during pregnancy and ... disorder, according to the research report, although it remains to ... hold the clues that will help unravel this potential link ...
... University in England have revealed that if patients who are ... to scale down the risk of blood clots, // as ... change the doses of warfarin, also known as Coumadin, according ... dying within two years, which can be reduced by about ...
Cached Medicine News:Health News:More People Come To India For Cosmetic Surgery 2Health News:Sunny Side Up - Vitamin-D deficiency linked to Schizophrenia 2
The opaque outer circle will white-out even the darkest iris, making your pupil the only spot of black in a sea of white....
This camouflaging lens features the solid black stripes of the lightning fast African zebra, on a white iris background....
Medpor Sphere Inserter. The Inserter is provided as a value added item to Medpor Orbital Implants....
Reusable blunt cannula with luer hub. Cannula length is 32 mm....
Medicine Products: